8-K
filed August 7, 2024, 7:59 PM ET
ticker CNSP
CIK 0001729427
other material
confidence high
sentiment positive
materiality 0.75
CNS Pharmaceuticals regains Nasdaq equity compliance after $9.9M share sale
CNS Pharmaceuticals, Inc.
- Shareholders' equity exceeds $5.0M, above Nasdaq's $2.5M minimum for continued listing.
- Sold 23,091,315 shares under A.G.P. agreement for gross proceeds of ~$9.9M.
- Cash on deposit $9.6M; company expects to fund operations through Q1 2025.
- Nasdaq Panel had granted final extension to Aug 12, 2024; delisting risk now resolved.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001683168-24-005311
- form_type
- 8-K
- ticker
- CNSP
- cik
- 0001729427
- company_name
- CNS Pharmaceuticals, Inc.
- filed_at
- 2024-08-07T23:59:59+00:00
- discovered_at
- 2026-05-14T18:03:14.337268+00:00
- generated_at
- 2026-05-31T11:49:42.902667+00:00
- sec_items
- ["8.01"]
- event_type
- other_material
- sentiment
- positive
- materiality_score
- 0.75
- calibrated_materiality_score
- 0.75
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001683168-24-005311
- json_url
- https://secwatch.observer/filing/0001683168-24-005311.json
- markdown_url
- https://secwatch.observer/filing/0001683168-24-005311.md
- text_url
- https://secwatch.observer/filing/0001683168-24-005311.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1729427/000168316824005311/0001683168-24-005311-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1729427/000168316824005311/cns_8k.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
KRMN
Selling stockholders price upsized secondary offering of 14M shares at $61/share for ~$854M gross proceeds
Karman Holdings Inc.
June 1, 2026, 5:28 PM ET
other_material
Items 1.01, 7.01, 8.01, 9.01
same SEC item: 8.01
same event type: other_material
similar materiality
Filing page
SEC filing
PECE
Peace Acquisition Corp closes IPO of 6M units at $10.00/unit, raising $60M
Peace Acquisition Corp.
June 1, 2026, 5:16 PM ET
other_material
Items 3.02, 8.01, 9.01
same SEC item: 8.01
same event type: other_material
similar materiality
Filing page
SEC filing
CWBHF
Charlotte's Web appoints BAT GC to board, closes debt conversion & US$10M investment
Charlotte's Web Holdings, Inc.
June 1, 2026, 5:13 PM ET
other_material
Items 5.02, 5.07, 8.01
same SEC item: 8.01
same event type: other_material
similar materiality
Filing page
SEC filing
MVIS
MicroVision seeks reverse stock split approval; ratio 1:5 to 1:15; annual meeting July 10, 2026
MICROVISION, INC.
June 1, 2026, 5:02 PM ET
other_material
Items 8.01, 9.01
same SEC item: 8.01
same event type: other_material
similar materiality
Filing page
SEC filing
IMRX
Immuneering reports 17.3-month median OS in Phase 2a pancreatic trial of atebimetinib
Immuneering Corp
June 1, 2026, 4:51 PM ET
other_material
Items 8.01
same SEC item: 8.01
same event type: other_material
similar materiality
Filing page
SEC filing
VDTA
Vertical Data launches Vertical Edge, a direct-ownership edge data center platform
Vertical Data Inc.
June 1, 2026, 4:47 PM ET
other_material
Items 8.01, 9.01
same SEC item: 8.01
same event type: other_material
similar materiality
Filing page
SEC filing
ORLY
O'Reilly Automotive adds $2.0B to share repurchase program, total authorized now $31.75B
O REILLY AUTOMOTIVE INC
June 1, 2026, 4:31 PM ET
other_material
Items 8.01
same SEC item: 8.01
same event type: other_material
similar materiality
Filing page
SEC filing
XAIR
Beyond Air receives Nasdaq panel grant for continued listing; must meet bid price rule by July 31, 2026
Beyond Air, Inc.
June 1, 2026, 4:30 PM ET
other_material
Items 8.01, 9.01
same SEC item: 8.01
same event type: other_material
similar materiality
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.